Voyager Therapeutics Announces Clinical Trial Update with VY-AADC01 for Advanced Parkinson’s Disease
June 26, 2017 07:05 ET
|
Voyager Therapeutics
CAMBRIDGE, Mass., June 26, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological...
Voyager Therapeutics Selects Lead Clinical Candidate for Huntington’s Disease
June 01, 2017 07:04 ET
|
Voyager Therapeutics
CAMBRIDGE, Mass., June 01, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological...
Voyager Therapeutics Reports First Quarter 2017 Financial Results and Corporate Highlights
May 09, 2017 16:10 ET
|
Voyager Therapeutics
VY-AADC01 interim Phase 1b data recently presented at American Academy of Neurology and American Association of Neurological Surgeons meetings; program on track to report 6-month data from Cohort 3...
Voyager Therapeutics Announces Additional Results from Phase 1b Trial of VY-AADC01 for Advanced Parkinson’s Disease
April 25, 2017 07:02 ET
|
Voyager Therapeutics
Improved Functional and Quality of Life Data Presented at the American Academy of Neurology (AAN) Meeting in Boston, MA Surgical Delivery Data Presented at the American Association of Neurological...
Voyager Therapeutics Announces Positive Interim Results from Phase 1b Trial of VY-AADC01 for Advanced Parkinson’s Disease
December 07, 2016 16:05 ET
|
Voyager Therapeutics
VY-AADC01 dose-dependently improved measures of motor function and enhanced response to levodopa at six and twelve months; administration of VY-AADC01 was well-tolerated Program on track to report...
Voyager Therapeutics Licenses Novel Gene Therapy Capsids from the California Institute of Technology
September 15, 2016 07:05 ET
|
Voyager Therapeutics
CAMBRIDGE, Mass., Sept. 15, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the...
Voyager Therapeutics and CHDI Foundation Collaborate to Develop Novel Gene Therapy for Huntington’s Disease
September 12, 2016 07:05 ET
|
Voyager Therapeutics
CAMBRIDGE, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the...
Voyager Therapeutics Provides Second Quarter 2016 Investor Update
August 11, 2016 07:05 ET
|
Voyager Therapeutics
VY-AADC01 Phase 1b Study for Advanced Parkinson’s Disease On Track to Report Six-Month Safety, Motor Function, and Biomarker Data from Cohorts 1 and 2 by Year-End 2016 Pipeline Advances with...